The present data on the use of mAb-Saporin conjugate to target TCblR appears to be specific for certain cancers and provides proof of concept for utilizing this receptor for targeted delivery of drugs and toxins and awaits confirmation of in vivo targeting efficacy of this pathway. This evidence concerns the gene CD320 and cancer.